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Background. Inclusion of multiple immunogens to target a single organism is a strategy being pursued for many experimental
vaccines, especially where it is difficult to generate a strongly protective response from a single immunogen. Although there
are many human vaccines that contain multiple defined immunogens, in almost every case each component targets a different
pathogen. As a consequence, there is little practical experience for deciding where the increased complexity of vaccines with
multiple defined immunogens vaccines targeting single pathogens will be justifiable. Methodology/Principal Findings. A
mathematical model, with immunogenicity parameters derived from a database of human responses to established vaccines,
was used to predict the increase in the efficacy and the proportion of the population protected resulting from addition of
further immunogens. The gains depended on the relative protection and the range of responses in the population to each
immunogen and also to the correlation of the responses between immunogens. In most scenarios modeled, the gain in overall
efficacy obtained by adding more immunogens was comparable to gains obtained from a single immunogen through the use
of better formulations or adjuvants. Multi-component single target vaccines were more effective at decreasing the proportion
of poor responders than increasing the overall efficacy of the vaccine in a population. Conclusions/Significance. Inclusion of
limited number of antigens in a vaccine aimed at targeting a single organism will increase efficacy, but the gains are relatively
modest and for a practical vaccine there are constraints that are likely to limit multi-component single target vaccines to
a small number of key antigens. The model predicts that this type of vaccine will be most useful where the critical issue is the
reduction in proportion of poor responders.
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INTRODUCTION
Chronic infectious diseases (e.g. malaria, tuberculosis, HIV) pose
major challenges for new vaccines since these pathogens have
evolved a variety of defense mechanisms that result in ineffective
immunological responses to their constituent immunogens. Several
strategies for trying to develop efficacious vaccines for these
diseases include:
1. The use of genome and proteome projects to enable the
systematic screening of all relevant pathogen proteins to
identify the best immunogens, especially for bacterial [1] or
parasitic diseases [2].
2. Improving the quantity or quality of the immune response by
engineering the immunogen [3,4] and through the use of
more aggressive adjuvants. Although increasing understand-
ing of the innate immune system [5] and the mechanisms of
adjuvant action is likely to yield significant advances, the use
of new adjuvants may be limited by safety or reactogenicity
considerations [6].
3. The use of multiple immunogens. This is a strategy being
pursued in a number of experimental vaccines. Although an
obvious approach, there is surprisingly little experience with
licensed human vaccines comprised of mixtures of defined
immunogens that target a single pathogen. There are many
human vaccines that contain mixtures of immunogens, but
the different components usually target immunologically
different pathogens, either different species or different
serotypes of a single species (e.g. Pneumonococcal vaccines).
Acellular pertussis vaccine is one multi-component, single
target vaccine that contains two to five defined components
[7] but even for this, there is debate as to whether the mixture
is better than a vaccine based on pertussis toxin alone [8].
There are two distinct measures of the performance of a vaccine.
1) Vaccine efficacy is determined by recording the incidence of
clinical episodes in a vaccinated group versus a control group over
a defined time. This provides a measure of efficacy in the
population based on the relative risk of contracting the disease. 2)
The proportion of the vaccinated population that achieve
a ‘‘protective’’ level of immunity e.g. for Hepatitis B, the
proportion of the population that generate an anti-HbSAg
antibody of 10 mIU per mL. For public health campaigns aimed
at generating herd immunity to chronic infections, the distribution
of individual risks is important, since poor responders may become
the reservoirs of infection [9]. Although minimum protective levels
are commonly assigned to vaccines, the basis for this assignment is
often difficult [10]. Where immune responses correlate with
subsequent protection, there is a continuous variation between
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In practice, gains in efficacy by adding multiple immunogens
will be balanced by the additional cost and complexity of
manufacture, the need for a common adjuvant, the increased risk
of adverse event as the immunogen load is increased, the
possibility of chemical interactions between the components
leading to inactivation of individual immunogens [12] and the
problems of immunological interactions leading to poor immune
response to one of more components. The vaccine complexity may
be further exacerbated by the need in some existing and
experimental vaccines to cover immunogenic diversity by inclusion
of different serotypes of each immunogen. This cost of increasing
the number of immunogens will depend on the delivery system
employed: for protein based vaccines, fusion proteins have been
used to deliver several immunogens as a single protein [13,14];
DNA based vaccines as either naked DNA [15] or part of a viral
deliver system [16] have been promoted, in part, on their ability to
deliver complex mixes of immunogens.
To provide a basis for more rational design of multi-component
vaccines, we have developed a mathematical model to investigate
the potential gains in efficacy generated by combination vaccines.
The model allows a comparison between the gains in efficacy from
adding multiple immunogens with gains from more potent
formulations or by choosing more efficacious immunogens and
delineates the limited set of conditions where multi-component
vaccines will be of practical importance.
METHODS
Data Base
NBCI Pubmed (http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?db=PubMed) was searched to find all references to ‘‘vaccine
AND clinical Trial[publication type]’’ published from 1/1/1999
to 9/16/2006. The QUOSA Information Manager (http://www.
quosa.com) [17] as used to download all PDF files accessible
through the NIH electronic library. 1668 files were obtained.
These were searched within QUOSA to find the terms ‘‘reverse
distribution’’ OR ‘‘reverse cumulative’’ anywhere within the text
of these 1668 PDF files. This search found 66 references. These
references containing reverse cumulative distributions [18] of
immune response were selected since these have the potential to
check summary information (geometric means and 95% confi-
dence limit) against the actual distribution of antibody responses.
Antibody geometric means and 95% confidence limits were
recorded for IgG levels, hemagglutination inhibition titers or
neutralization titers for post primary vaccination series and for
post boost antibody levels where the booster vaccine was not part
of the initial vaccinations (e.g. for a 2, 4, 6 months infant
immunization schedule followed by a 12 months boost, the
geometric mean antibody level and confidence limits were
recorded for months 7 and month 13 antibody levels). Antibody
levels were not analyzed for pre-vaccination samples, samples
collected part way through a vaccination series or for pre-boost
samples. In all, 574 antibody distributions were recorded from 40
of the 66 papers. The most common reason for rejecting data from
individual papers was the lack of quoted confidence intervals.
Geometric mean antibody level and confidence intervals were
recorded regardless of whether the paper described the corre-
sponding reverse cumulative distribution. Generally the geometric
mean antibody level and the upper and lower 95% limits were
stated in the papers. In two cases, the quoted figures were
internally inconsistent and these distributions were not included in
the analyzed data set.
From the geometric mean antibody level, the 95% confidence
interval of the means and the sample size, the standard deviations
of the log transformed data were calculated, the 95% limits on
distribution of the log transformed immune responses and the ratio
of the upper to lower 95% limits of the non-transformed
population distribution calculated (the fold range) and tabulated
(Supplementary files Database S1 and Text S1). In principle, to
calculate the standard deviation from the published confidence
interval, it is necessary to know if the original authors used a t
distribution or a normal distribution to calculate confidence
intervals and this is often not cited in the publication. In practice,
since most of the data sets have large numbers of subjects, this
made little difference. In calculating the fold range, the median
values were 64 and 68 on the assumption that all authors used a t
distribution or a normal distribution, respectively. Thus in
choosing representative values (9, 65 and 5000) of the fold range
to use for modeling, we have picked rounded values that lie
between the estimates from the two methods for the lower 2.5%
quantile, median and upper 2.5% quantile, respectively.
These papers contained 408 usable post vaccination reverse
cumulative distributions. They were not examined further if the
distribution did not include the complete antibody range of
subjects, if the number of subjects in the distribution was not
recorded or if there were other factors missing that made
interpretation impossible (e.g. the antibody scale was missing for
the distributions in one paper). For each immunogen that was
present more than once in the data base, a distribution was chosen
where the complete reverse cumulative distribution was available,
where the quality of the published distributions allowed a high
quality digitization and curves with ranges and geometric mean
antibody levels close to the center of the range for that
immunogen. The published distribution was digitized from the
PDF file, individual data points extracted, the geometric mean
antibody and 95% confidence limits of the geometric mean
antibody calculated and compared to the published values to
check on the accuracy of the digitization. The distribution of the
log transformed antibody data were graphically compared with
a normal distribution using a Q-Q plot and numerically through
the use of a Shapiro-Wilk test using the W statistic as a measure of
departure from normality [19].
Model
The model assumes that there is a monotonically increasing
relationship between immune response and probability of pro-
tection, that there will be a range of responses occurring in the
vaccinated population and that the responses to different immuno-
gens in a vaccine will vary from being negatively to tightly positively
correlated. In the model presented here, we assume that the
immunity induced by each component is ‘‘additive’’. Formally, we
assume that the additive response conforms to Bliss independence
[20,21]; the probability of infection (or disease, depending on the
vaccine) in the presence of an immune response to a mixture is the
product of the probabilities of the infection in the presence each
separate immune response. Thus if each of two immunogens
reduces the risk of disease to 1/2, the combination will reduce the
risk to 1/4 (i.e. 1/261/2).
The relative risk of the ith subject attributed to the Xij immune
response to the jth immunogen was calculated using the Hill
function [22].
RRij~1{ Xij
 
bj
   aj
.
1z Xij
 
bj
   aj   
Where bj is the immune response required to give a RR of 0.5. In
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zero as the immune response increases. The value aj=1 was used
for all simulations reported in this paper, but this fixing of aj=1
does not hinder the generality of the model (see below).
The relative risk (RR) of the ith subject contracting disease
following vaccination with a mixture of n immunogens is
RRi~P
n
j~1
RRij
The efficacy of the vaccination in the population was calculated as
1-mean relative risk, where mean relative risk is calculated by
taking the expectation over a population assuming the log
transformed immune responses are normally distributed. The
details of these calculations are given in the Supplementary file
Text S1. The expectations were calculated for each of many
different populations that each have different geometric means.
For example, if m1 is the mean of the log transformed and
standardized immune response of the first component for
a population (i.e., the mean of log10(Xi1/b1)), then the geometric
mean of that population is 10
m1. The standard deviation of the log
transformed responses of a population is denoted s1. In this paper
for interpretability we use the ‘‘fold range’’, which is a simple
function of that standard deviation (specifically, 10
3.92s1), and the
fold range is the ratio of the upper to lower quantiles of the middle
95% of each immune distribution (see Supplementary file Text S1
for derivation).
We established that the log transformed antibody level is
approximately normal (see Results) and using the assumption that
the distribution of antibody responses is a useful surrogate for the
distribution of immune responses in general, the published 95%
confidence intervals for the geometric mean immune response of
the population were used to calculate and compare fold ranges in
the 574 combinations of antigens and populations vaccinated in
the assembled database. Since the antibody responses of trials are
commonly quoted as geometric mean responses, we will use
‘‘geometric mean’’ in this paper but note that as the log antibody
responses fit a normal distribution, the geometric mean of
a population is also its median.
By properties of the normal distribution, we can show the
generality of the model. Specifically, the mean efficacy from the
model with aj=1, mean=mj, and standard deviation=sj is
equivalent to the mean efficacy from the model with aj=a,
mean=mj/a and standard deviation=si/a, for any a.0
The increased immunogenicity required for a single component
vaccine to match the protection afforded by a mixture was
calculated by comparison of the efficacy or % protected values for
the mixture with the mean efficacy vs. immune response or %
protection vs. immune response relationships for a single compo-
nent vaccine.
For modeling mixtures of immunogens that individually
generate different levels of protection, the most active immunogen
as judged by the average level of efficacy in the population, was
used as the comparator immunogen and the ratio its geometric
mean to those of the 2
nd or 3
rd immunogens was kept constant as
the geometric mean immune response to the first antigen was
varied. For example, if the second component has 10% of the
geometric mean of the first component, the geometric mean
antibody to the second antibody will be 0.1 unit when the
geometric mean antibody to the first immunogen is 1.
An R package (Supplementary file Software S1. See Supple-
mentary file Text S1 for instructions on how to download a copy
of the package and on its use) was developed to calculate the
efficacy of mixtures, the proportion protected and the increase in
immune levels required for a single component vaccine to match
a mixture. The R package is the definitive version of the model. A
simplified version of the model is also available as a Microsoft
Excel spreadsheet (Supplementary file Spreadsheet S1.) This needs
to be downloaded and decompressed prior to use. Instructions for
use are contained within the spreadsheet.
RESULTS
Distribution of human immune responses to
conventional vaccines
A database of published human immune responses to conventional
vaccines was used for assigning parameters to the model. Thirty of
the published reverse cumulative distributions [18] of the vaccine
responses to individual immunogens were used to determine the
distribution of the antibody responses. In all cases, as judged by the
shape of the q-q plot, the distribution of the log transformed data
were close to normal (mean Shapiro-Wilk [19] W=0.96). 13/30
had a significant departure (p,0.05 without correcting for
multiple comparisons) from normality. However, even for these,
the Shapiro-Wilk coefficient was .=0.88 suggesting that the
deviation from normal was small. For the vaccine trials that gave
the greatest departures from normality (a hepatitis A vaccine [23]
and a S. pneumoniae type 19F vaccine [24] trial), the distribution of
the log transformed data from other 3 other trials examined with
each of these vaccines were not significantly different to a normal
distribution (data not shown).
The observed fold range depends on the immunogen. Over the
whole set of data analyzed, the median fold range was
approximately 65 (95% of the observed fold ranges were
approximately between 9 to 5,000 fold depending on the
assumptions used to analyze individual data–see ‘‘Materials and
Methods’’ for details).
Protein toxoid responses (diphtheria, tetanus and pertussis)
tended to have smaller fold ranges that other vaccines, but this
was not specific to protein immunogen since the fold range of
responses to the Hepatitis B was the largest observed. Even for
conjugate vaccines that shared the same carriers, the fold range of
responses varied significantly. For example, in Fig. 1, there are 23
determinationsofthefold range of responseto S.pneumoniae serotype
6B and 9V in paired trials where the same carrier is used in each
pair. In these studies, serotype 6B has a significantly higher fold
range than 9B (P,0.0001, Z=4.18, Wilcoxon signed rank test).
For a single vaccine, there is considerable variation in the
measurement of that fold range in different trials. For 5 of 18
immunogens tested in infants, there was a significant inverse
correlation between the geometric mean immune response and fold
range (Table 1), but even where significant, this only accounts for
part of the variation. The database predominantly reports vaccine
trials in infants. Where the same vaccine was used in older age
groups the fold range usually increased with age, although whether
this is due to prior exposure or a direct effect of aging could not be
assessed. In one case, a wider fold range was associated
a measurement of the response prior to the peak response[25].
On the basis of these results, we chose the underlying
distribution for modeling the efficacy of combination vaccines as
a normal distribution on the log immune response such that the
fold range is 65 on the untransformed responses.
Mixtures of independent immunogens with equal
individual efficacy
Fig. 2 illustrates the predicted efficacy for vaccines with one, two
or three immunogens as a function of the geometric mean
Multi-Component Vaccines
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give a narrow, median or wide fold range of immune responses.
In all models, the immune responses for each component are
scaled so a person with an immune response of 1 unit would have
a 50% decrease in risk. For this model, we assume that for
vaccines with two or three immunogens, each immunogen
induces the same geometric mean response in the population;
has the same fold range of immune responses, and has no
correlation between the immune responses to the component
immunogens. For vaccines with a single component, even though
the risk of infection to an individual is determined by the
individual immune response, the efficacy in the population
depends on both the geometric mean and the fold range of
immune responses in the population. Measures that increase the
average immune response (e.g. more active adjuvants or altered
vaccination regimens) have a bigger impact on efficacy for
vaccines that have a narrow fold range of responses, than
vaccines that have a broad fold range.
As expected, addition of a second or third vaccine component
increases the efficacy of the vaccine. There are two effects: an
increase in efficacy for any given immune response; a steeper
antibody: efficacy response for the mixtures.
For developing vaccine design strategies, it would be useful to
predict the relative impact of different vaccine strategies. Using
a single immunogen vaccine as the standard, the efficacy of
a mixture as a function of the efficacy of a single immunogen
vaccine has been plotted (Fig. 3a) or the increase required in
immune response from a single immunogen vaccine to match the
increased efficacy of a mixture (‘‘relative immunogenicity’’,
Fig. 3b). In both cases, the outcomes have been plotted over
a range of efficacies for the single immunogen comparator
vaccine.
The efficacy of the mixture does not depend on the fold range
of responses for the individual immunogens (Fig. 3a). However,
the relative immunogenicity depends on both the geometric
mean and fold range of the immune responses of the individual
components.
The gains by mixing two or three immunogen are relatively
modest: For example for a single immunogen vaccine that gives an
average efficacy in the population of 50% and has a fold range of
Figure 1. The fold range of the immune response reported for 396 immunogens in vaccine trials in infants. Each point is the ratio of the
estimated 97.5
th percentile antibody response to the 2.5
th percentile response (i.e. the 95% range) in the post vaccination sera. Most vaccine trials
contained several immunogens. Eleven serospecificites are reported for pneumonococcal vaccines. The order from top to bottom is serotypes 1, 3, 4,
5, 6B, 7F, 9V, 14, 18C, 19F and 23 F. The four meningococcal vaccine results are from the only infant trial in this data base and are a single
determination of each of the A, C, W173 and Y specificities. Polio values are ranges for neutralizing activity for Polio 1, 2 and 3, respectively, from left
to right. References to the individual trials are contained in supplementary file Database S1.
doi:10.1371/journal.pone.0000850.g001
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overall efficacy to 75%. The model predicts that this gain is
equivalent to a four fold increase in immunogenicity for a single
component with larger gains for vaccines that give a greater fold
range in responses.
By contrast, mixtures of immunogens are predicted to have
large impacts on the proportion of poor responders in the
population and this impact is highly dependent on the fold range
induced by the vaccine. In Fig. 3c the proportion protected with
a mixture is plotted as a function of the proportion protected by
a single immunogen. The data for this figure assume that the
‘‘protected’’ individuals have .90% decreased probability of
disease. Qualitatively similar results are obtained with other
‘‘protection’’ thresholds (data not shown). A large increase in
immunogenicity is required for a single vaccine to match the
percent protection induced by a mixture and is largely in-
dependent of the fold range (Fig. 3d).
Mixtures of independent immunogens with unequal
individual efficacy
The efficacy of mixtures of immunogens that when used
individually give geometric mean responses that are 10%, 33.3%
and 50% of the geometric mean response of the most efficacious
component, are plotted in Fig. 4a as a function of the efficacy of
the best component acting alone and their relative immunogenic-
ity in Fig. 4b. As the efficacy of the second or third components
drops compared to the efficacy of the most active component, the
gains obtained by mixing on overall efficacy (Fig. 4a) or the
proportion protected (Fig 4c) decrease substantially as does the
relative immunogenicity of a single component vaccine that would
Table 1. Spearman rank correlation between geometric mean
antibody responses and fold range of antibody responses in
vaccine trials in infants.
......................................................................
Vaccine Immunogen No. of trials
Spearman rank
correlation
Pneumonococcal 1 13 20.02
31 3 20.35
4 23 0.10
5 13 0.08
14 23 20.42*
18C 23 20.30
19F 23 0.20
23F 23 0.04
6B 23 0.21
7F 13 0.24
9V 23 20.37*
HiB PRP 28 20.37
Diphtheria DT 30 20.11
Pertussis FHA 13 20.19
Pertactin 12 20.62*
PT 22 20.45*
Hepatitis B HbS 13 20.44*
Tetanus TT 20 20.04
*P 0.017 to 0.045
doi:10.1371/journal.pone.0000850.t001
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Figure 2. Model prediction for the efficacy of single component vaccines (solid line), two component vaccines (dashed lines) and three
component vaccines (dotted lines) as a function of the mean immune response elicited in the population to each component. This data set
assumes that each component contributes equally to the efficacy, the immune responses to the individual immunogens are not correlated and that
the log transformed distribution of the immune response is normal with a fold range of 9 (blue), 65 (green) and 5,000 (red).
doi:10.1371/journal.pone.0000850.g002
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the proportion protected (Fig. 4d).
Mixtures of immunogens with correlated immune
response and with equal individual efficacy
Correlation of the immune response of the components in
a mixture is predicted to have an impact on both the overall
efficacy of the mixture and on the proportion of people protected
by the mixture (Fig. 5a to 5d). Immunogens that induce
independent immune responses giving greater increases in efficacy
in the mixture compared to immunogen that give highly positively
correlated immune responses. Theoretically, immunogens may
give negatively correlated responses. A negative correlation
enhances the efficacy and proportion protected compared to
independent responses.
DISCUSSION
This study predicts that under optimum conditions, useful gains in
efficacy and in the proportion of responders in a community can
be obtained through the use of vaccines containing mixtures of
immunogens targeting a single pathogen. This analysis suggests
that the key factor for multi-component vaccines is the quality of
the immunogens and the potency of the formulation. Especially for
strategies aimed at improving the average efficacy of a vaccine, the
gains from mixing several immunogens are relatively small and are
similar to the gains obtained by increasing immunogenicity by
approximately 3 to 5 fold.
Figure 3. Effect of the diversity of immune response on efficacy and percentage of the population protected by two component (dashed lines)
and three component vaccines (dotted lines) for vaccines using the same model parameters as Fig. 2 where each component has the same
average immunogenicity. (a) The efficacy of a two or three component (grey solid line) as a function of the average efficacy of single component
vaccines. Diversity of the immune response has no impact on the efficacy of the mixed vaccine so the curves for the three component vaccines
(dotted upper lines) coincide as do the curves for the two component vaccines (dashed middle line). (b) Relative immunogenicity that would be
needed with a single component vaccine to match the efficacy of a two or three component vaccine as a function of the average efficacy of single
component vaccines. The relative immunogenicity is the ratio of the immune response required in a single component vaccine to the immune
response of the best immunogen in a multi-component vaccine with similar efficacy (c) Comparison of the percentage of the population protected
(relative risk of 0.1 or less) of a two or three component vaccine to the percentage protected with a single component vaccine (grey solid line) as
a function of the percentage protected with single component vaccines of varying efficacy. (d) Relative immunogenicity that would be required with
a single component vaccine to match the percentage protected with a multi-component vaccine as a function of the percentage protected with
single component vaccines of varying efficacy. The relative immunogenicity can only be determined over the part of the range where ,100% of the
population given a mixed vaccine is protected.
doi:10.1371/journal.pone.0000850.g003
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immunogenicity is seen in different versions of some current
vaccines. For example, in a large trial of infants vaccinated with
three different acellular pertussis vaccines there was a 3 fold
difference between the geometric mean anti-pertussis toxin level
and a 5 fold difference between the anti-filamentous hemagglutin
levels between two of the vaccines [7]. Thus, creation of multi-
component vaccines is unlikely to be justifiable until it is known
that careful optimization of formulation results in a vaccine that
just fails to achieve the necessary efficacy or the proportion
protected.
Depending on the immunogen, addition of adjuvants can make
a large difference. An extreme example is the 10,000 fold
difference recorded between the antibody response to a non-
adjuvanted hepatitis B vaccine and to the same immunogen after
the addition of the AS02 adjuvant [26]. Comparison of the
currently used alum adjuvanted hepatitis B vaccine with the same
vaccine after the addition of the immunostimlatory oligonucleotide
CPG 7909 gives a 10 fold increase in antibody after two
vaccinations [27]. A 10 fold increase in antibody response would
give a comparable or greater increase in efficacy than the increase
in efficacy predicted by this model for adding a second or third
immunogen.
Two other immunogen related factors impact the predicted
gains. The gain in efficacy from generating a mixture does not
depend on the diversity of the immune response. However, a larger
increase in antibody is required to give a similar increase in
efficacy in a vaccine that has a highly diverse immune response
compared to a more homogeneous response. When compared to
other methods of improving efficacy, mixtures may be more
attractive for immunogens that generate a diverse response. On
the other hand, with immunogens that give a smaller variation in
antibody responses, larger gains in the proportion of responders is
possible with mixtures. The correlation of the immune responses
between different immunogens also influences the gains: for the
additive model considered here, mixtures of immunogens that give
a highly correlated response give smaller gains in both efficacy and
in the proportion of the community protected than immunogens
with independent responses.
The model predicts that use of mixtures may be more useful for
decreasing the proportion of poor responders in a community than
in increasing the overall efficacy. If the increase in efficacy or the
Figure 4. Effect using immunogens that elicit different levels of immunity in a two component (dashed lines) or three component (dotted lines)
vaccines on efficacy and the percent population protected. Model assumes that the diversity of the immune response generated by each
component is similar (fold range is 65 fold) and that the immune response to the individual components is not correlated. Vaccines contain a second
or third immunogen that generate 1/10 (red), 1/3 (green), 1/2 (blue) or equal geometric mean immune responses (black) to the geometric mean of
the first component. Other details are described in the Figure 3 legend.
doi:10.1371/journal.pone.0000850.g004
Multi-Component Vaccines
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the gain in the proportion protected is approximately twice the
gain in efficacy. For example, the gain in efficacy by mixing two
immunogens each of which give a mean 50% efficacy and for
which the responses are independent, is equivalent to improving
the immunogenicity of a single component by 3.8 fold (Fig. 3b,
binary mix, fold range 65) with a corresponding increase in
efficacy from 50 to 75%. By contrast, the gain in proportion
protected with the same combination that gave 50% protected, is
equivalent to increasing the immunogenicity of a single compo-
nent by 8.25 fold with a corresponding increase in proportion
protected from 50 to 97.6%.
The gains in the proportion protected, are highly dependent on
the correlation between the immune response (Fig. 5d). If there is
a low correlation between the immune responses, then it is likely
that a person who is a poor responder to one immunogen, will be
at least an average responder to another immunogen, and
therefore will be protected. If the responses are highly correlated,
then in this model a person who is a poor responder to a single
immunogen will still receive some gain from a mixture, (overall
response at least as good as doubling the antibody level), but will
still be a relatively poor responder overall.
Using the assumption of an additive response, for using multi-
component to either boost overall efficacy or the proportion of
people protected, a major limitation is the need to have
immunogens that individually give similar efficacies. It seems
unlikely that once the best immunogen has been found for
a particular pathogen, and the immunogenicity of the vaccine
formulation using that immunogen optimized, that there would be
multiple other immunogens that would give similar protection.
Therefore, most practical vaccines are unlikely to contain more
than two or three immunogens targeting a single pathogen,
especially as many vaccines being developed may also require
multiple variants of each immunogen to overcome antigenic
Figure 5. Effect of the correlation of immune responses to the immunogens in a two component (dashed lines) or three component (dotted
lines) vaccine on efficacy and the percent population protected. Model assumes that the diversity of the immune response generated by each
component is similar (fold range is 65 fold) and that the level of the immune response to the individual components is similar. Immune responses
have a correlation coefficient (r) of 1 (lower black line), 0.75 (red), 0.5 (yellow), 0.25 (green), 0 (upper black), 20.25 (blue) and 20.5 (purple). Other
details are described in the Figure 3 legend.
doi:10.1371/journal.pone.0000850.g005
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or percent protected from making a binary or even tertiary
mixture are relatively modest, it would also make it unlikely that
mixtures of components that are poor immunogens, e.g. fail to
generate a significant biological response in a Phase 2 trial, would
form a useful vaccine unless there was some major synergistic
response that was undetectable in single antigen trials.
The development of this model highlighted several areas where
there was little available information on human responses to
vaccines in general or to mixed immunogens in particular. There
are few reports on the details of the relationship between the
strength of a vaccine induced response and the subsequent relative
risk of disease. This is a difficult relationship to measure since it
requires a high disease incidence or large group sizes and may
contain substantial error. Although different relationships have
been proposed in individual studies, all are broadly compatible
with the simplest relationship, the Hill function, chosen for this
model. The use of the Hill function chosen for this study
potentially allows a wide variety of response/protection relation-
ships to be modeled and this may be important in modeling
individual vaccines where the relationship between immune
response and protection is known or measured.
Given the large number of trials published with multi-
component vaccines in which individual immune responses to
the component immunogens have been measures (e.g. most of the
trials referenced in the data base used for this study, supplemen-
tary file Database S1), there is surprisingly little published data on
the correlation between the human immune response to different
antigens in a multi-immunogen vaccine. As a result, we have
chosen to investigate the range of possible correlations rather than
chose literature values.
Immunological interference is a concern in multi-component
multi-target vaccines where the immune response to one
component decreases the response and thus the protection to
a different component. Reflecting this concern, the FDA in its
guidance for industry for the evaluation of combination vaccines
emphasizes the importance of non-inferiority tests to show that the
immune response to each component of a vaccine is not less than
the response to the same component in a single component
vaccine[28,29]. However this guidance is specifically for multi-
target vaccines (either multiple diseases or multiple serotypes of
a single pathogen species) and not for the multi-component, single
target vaccines considered in this study.
Immune interference is less likely to be a problem for multi-
component vaccines targeting a single organism. In multi-target
vaccines, a strong response to one immunogen could decrease an
otherwise marginal response to a second immunogen and render
the subject vulnerable to infection with the pathogen correspond-
ing to the second immunogen. In single target vaccines, the major
problem with antigenic interference would only occur in the
unlikely case of a weak response to one immunogen substantially
decreasing the strong response to a second immunogen. In any
case, for a multi-component, single target vaccine, the critical test
is if the combination gives a better efficacy than the individual
immunogens, and this could occur even if the immune response to
the individual components was weaker in the combination than
individually. This is not covered by the existing FDA guidance.
Despite the abundance of data on human trials for multi-
component, multi-target vaccines, the development and regulatory
considerations for multi-component, single target vaccines remains
to be fully developed.
This model assumes that protection from the immune response
to each component is additive as this is the simplest assumption for
how the individual responses will combine to determine the overall
efficacy of the vaccine in an individual. Theoretically, either
a synergistic effect, where the overall efficacy was greater than
predicted, or a less than additive response could apply to specific
combination vaccines. One extreme case of the latter situation was
considered in developing this model: where the efficacy of the
mixture was equal to the efficacy of the best component (i.e. no
additive response at all). Under these conditions, the combination
could give substantial improvement compared to the individual
vaccines, but this increase was critically dependent on the
correlation between the responses to the individual components:
the increased efficacy required a low correlation between
individual responses (results not shown).
For all examples analyzed in this study, antibody level is used as
a measure of immunity. However, the model is general and other
measures, e.g. levels of cytotoxic T-lymphocyte (CTL) responses
could be substituted with some provisos, including a consideration of
how protective responses to different antigens are correlated in the
population and whether the additive model applies. The correlation
of protective responses may be particularly important for peptide
based CTL vaccines containing a restricted number of epitopes that
are in turn HLA restricted. However, we would expect the same
generalresults:thegainsinadding multipleantigenswillberelatively
modest and only achieved where each individual antigens elicits
a broadly similar protective effect and that the complexity of
a vaccine may be further limited by the need to include multiple
variants of each antigen to protect against antigenic polymorphisms.
In conclusion, after optimizing immunogen choice and
formulation, significant gains in efficacy and the proportion of
the population protected by a vaccine may be obtained by
addition of further antigens targeting the same pathogen. While
the gains may be significant on a public health level, they are likely
to be relatively small. In one sense this makes decisions to proceed
with a multi-component vaccine simpler: unless each of the
component antigens have demonstrable activity, it is unlikely that
the mixture will be useful. On the other hand, demonstrating the
benefit of a mixture over a single component vaccine may be
difficult and require careful trial design. In some cases, justification
for the mixture may depend only on a theoretical consideration of
the efficacy of the individual components and rely on procedures
such as the model presented in this paper.
SUPPORTING INFORMATION
Text S1 Multi-component, single target vaccine R program
derivation and instructions. This file contains further details of the
derivation of the model, instructions for downloading and
installing the definitive version of the model written in the R
statistical programming language, instructions for using the model,
and examples of input and output from the model.
Found at: doi:10.1371/journal.pone.0000850.s001 (0.45 MB
PDF)
Database S1 Database of antibody responses from published
trials. This file contains the dataset of the magnitude and range of
responses.
Found at: doi:10.1371/journal.pone.0000850.s002 (0.16 MB
XLS)
Spreadsheet S1 Multi-component, single target vaccine Excel
spreadsheet. This is a version of the model presented as an Excel
spreadsheet and designed for a simpler user interface than the R
program version. It generates a more restricted range of output
compared to the R version. This file must be downloaded and
decompressed before use. Instructions for use are included in the
spreadsheet.
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PLoS ONE | www.plosone.org 9 September 2007 | Issue 9 | e850Found at: doi:10.1371/journal.pone.0000850.s003 (4.23 MB ZIP)
Software S1 Multi-component, single target vaccine R program
software package. The R package containing the model.
Instructions for unzipping and installing this program are
contained in the supplementary file Hbimdetails.pdf
Found at: doi:10.1371/journal.pone.0000850.s004 (0.60 MB ZIP)
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